GLP-1s for Adolescents: What the Evidence Supports, and What It Cannot Yet Tell Us

Where the evidence stands

Systematic reviews and meta-analyses of randomised controlled trials in adolescents with obesity or overweight without diabetes have found meaningful weight reduction with GLP-1 receptor agonists, semaglutide in particular. That is a real evidence base, and it supported approval in this age group.

It is also considerably smaller than the adult evidence base. SURMOUNT-1 randomised 2,539 adults. Adolescent trials are smaller, fewer, and shorter. Long-term follow-up into adulthood — which is the timeframe that matters for a drug started at fourteen — does not exist yet, and cannot for another decade.

What is genuinely different about treating adolescents

Growth and development. Adolescence involves bone accrual, hormonal change and body-composition shifts that adult trials do not model. Peak bone mass is largely established during these years, and the lean-mass evidence in adults — roughly 20% to 40% of weight lost — has no adolescent counterpart.

Duration. If obesity is chronic and treatment holds its result only while present, a sixteen-year-old starting treatment is contemplating decades. No trial addresses that horizon, and nobody has observed it.

Nutrition. Appetite suppression in a growing person raises questions about adequacy of intake that do not arise the same way in adults.

The disordered-eating question

Adolescence carries the highest incidence of eating disorder onset, and a medication whose primary effect is appetite suppression sits directly on that risk. Screening before starting, and monitoring during treatment, is not an optional extra in this age group.

It is also something a questionnaire cannot do. It requires a clinician who can ask follow-up questions, notice what is not being said, and involve family appropriately — which is a different service from an intake form, whatever that form asks.

What a specialist assessment covers that an intake form does not

• Growth velocity and pubertal stage, and how treatment interacts with both.
• Bone accrual, which largely completes during these years.
• Nutritional adequacy under appetite suppression in a growing body.
• Screening for disordered eating, with follow-up rather than a checkbox.
• Family context, which determines whether any plan is sustainable.
• Psychological wellbeing, assessed rather than asked about.

None of that is exotic. It is ordinary paediatric practice, and it is the reason this indication belongs in a specialist setting.

Why we publish no provider comparison for this

We do not compare providers for adolescent treatment and we do not publish pricing comparisons aimed at it. Not because prices differ, but because the decision should not be made on price and a comparison table implies it can be.

Adolescent obesity treatment belongs with a paediatric specialist who can assess growth, development, nutrition, psychological wellbeing and family context together. That is a different service from a telehealth intake, and presenting the two as interchangeable would be the most consequential thing we could get wrong on this site.

On compounded products specifically

Everything this site says about compounded preparations applies with more force here. They are not FDA-approved, they have not been through trials in any population, and no adolescent trial has studied one.

If treatment is indicated for an adolescent, that is an argument for an approved product prescribed by a specialist — not for the cheapest route. The price difference between an approved product and a compounded one is the smallest consideration in this particular decision.

What this costs, and where the money actually goes

Whatever the clinical question on this page, the financial one behind it is the same for almost every reader: this is an indefinite treatment, and the figure that matters is the monthly cost at a maintenance dose rather than the advertised entry price.

The Zepbound label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. Recommended maintenance dosages are 5, 10 and 15 mg, and increases are directed no sooner than every four weeks based on tolerability and response. So an advertised entry price describes roughly four weeks of a treatment most people take for years, and comparing providers on it compares them on a price nobody pays after month one.

Coverage beats every self-pay route by an order of magnitude. Establishing whether you qualify takes one phone call and is worth more than any price comparison.

Three mechanisms separate an advertised figure from what you pay. A required membership, which runs from $19.99 to $149 a month across the providers we track. Dose-escalation pricing, where the monthly cost rises as you titrate. And introductory rates, which apply to one month of an indefinite course — eleven programmes advertise one, and all are excluded from every ranking we publish.

The single question that resolves most of this is what you will pay at 10 mg, including every required fee. A provider who answers that plainly can be compared accurately, which is generally to the advantage of providers with nothing to hide.

How to check any claim on this page for yourself

Everything above should be checkable, and most of it is. Trial claims resolve to a registry entry and a peer-reviewed publication; regulatory claims resolve to an agency document; pricing claims resolve to a provider’s own published page read on a stated date.

Where we could not verify something, we say so rather than rounding it into confidence. Every pharmacy relationship on this site carries a reported rather than verified label, because not one provider has named its fulfilling pharmacy and registration class to us. That is the field we would weight most heavily if we had it, and it is the question worth putting first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.

Four checks take about ten minutes between them. Confirm your prescriber holds a current licence in your state, through that state’s medical board rather than through the provider’s own page. Confirm the fulfilling pharmacy is licensed, and registered as a nonresident pharmacy in your state if it ships from elsewhere. Search the pharmacy’s name against FDA warning letters and recall notices, both public. And ask for a certificate of analysis matched to the batch number on your vial.

None of that establishes that the medicine in your hand is safe. It establishes that the parties involved are inside the regulatory system and currently authorised, which is a floor rather than a guarantee. The honest framing is that you are reducing risk rather than eliminating it — and a provider unwilling to give you the names needed to run those checks has told you something worth knowing.